- Nimotuzumab combined with concurrent chemo-radiotherapy in patients with locally advanced cervical squamous cell carcinoma: A randomized, controlled, open-label, multicenter studyWang, J.; Jiang, P.; Wei, L.; Zou, L.; Li, X.; Wang, C.; Sun, X.; Ding, L.; Yuan, X.; Cheng, H.; Wu, D.; Cai, R.; Yin, R.; Zhang, J.; Qiu, H.; Wang, T.; Gao, K.; Zhuo, Y.; Zhang, Y.; Zhao, F.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial.Chen, MingYuan; Huang, Peiyu; Chen, Xuyin; Ding, Xi; Ling, Guo; Mo, Hao-Yuan; Duan, Chongyang; Ling, Li; Zou, Xiong; Liu, You-Ping; You, Rui; Xie, Yulong; Cao, Jingyu; Liu, Sihan; Wang, Zimeng; Yang, Qi; Qiu, Fang; Hua, Yijun; Cao, Kajia; Luo, Dong-HuaAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- Nab-paclitaxel plus cisplatin versus docetaxel plus cisplatin and 5-FU induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: A multicenter parallel controlled phase III trial.Lv, Xing; Zeng, Qi; Zhang, Weijun; Cheng, Hao; Xia, Weixiong; Yanqun, Xiang; Liang, Hu; Cao, Xun; Chen, Xi; Zhan, Zejiang; Deng, Ying; Zhou, Jiayu; Zhang, Lulu; Liang, Chixiong; Huang, Haoyang; Huang, Yingying; Cai, Zhuocheng; Guo, XiangAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.
4被引8阅读
